Case Study Reveals Important New Details About Rare Second Cancers Related to CAR-T Therapy

A new detailed analysis of a patient’s second cancer after receiving CAR-T therapy for the initial cancer provides rare but important insights intended to offer helpful guidance for oncologists and pathologists about the clinical presentation and pathologic features involved in a CAR-T related second cancer. The finding was reported June 12, 2024, in the New England Journal of Medicine. The article is titled “Indolent CD4+ CAR T-Cell Lymphoma After Ciltacel CAR T-Cell Therapy.”

Login Or Register To Read Full Story